AR071733A1 - Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma - Google Patents
Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasomaInfo
- Publication number
- AR071733A1 AR071733A1 ARP080104606A ARP080104606A AR071733A1 AR 071733 A1 AR071733 A1 AR 071733A1 AR P080104606 A ARP080104606 A AR P080104606A AR P080104606 A ARP080104606 A AR P080104606A AR 071733 A1 AR071733 A1 AR 071733A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- type
- use according
- proteasome inhibitor
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Abstract
La presente se refiere al uso de un anticuerpo anti-CD20 tipo II para la manufactura de un medicamento para el tratamiento del c ncer, especialmente de c nceres que expresan CD20 en combinacion con un inhibidor de proteasoma. Reivindicacion 4: El uso de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque dicho anticuerpo anti-CD20 tipo II tiene una relacion de las capacidades de union a CD20 en celulas Raji (ATCC-No. CCL-86) de dicho anticuerpo anti-CD20 tipo II en comparacion con rituximab de 0,3 a 0,6. Reivindicacion 8: El uso de acuerdo con cualquiera de las reivindicaciones 1 a 7, caracterizado porque dicho inhibidor de proteasoma se selecciona del grupo formado por aldeh¡dos pept¡dicos, boronatos pept¡dicos, epoxicetonas pept¡dicas o salinosporamida A. Reivindicacion 10: El uso de acuerdo con cualquiera de las reivindicaciones 1 a 9, caracterizado porque uno o m s agentes diferentes citotoxicos, quimioterapeuticos o anticancer¡genos adicionales o compuestos que aumentan los efectos de dichos agentes son administrados. Reivindicacion 11: El uso de acuerdo con cualquiera de las reivindicaciones 1 a 10 caracterizado porque el c ncer que expresa CD20 es un linfoma No Hodgkin de Celulas B (NHL).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07020820 | 2007-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071733A1 true AR071733A1 (es) | 2010-07-14 |
Family
ID=38973774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104606A AR071733A1 (es) | 2007-10-24 | 2008-10-22 | Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma |
Country Status (16)
Country | Link |
---|---|
US (4) | US20090110688A1 (es) |
EP (1) | EP2205318B1 (es) |
JP (1) | JP5469073B2 (es) |
KR (1) | KR101280733B1 (es) |
AR (1) | AR071733A1 (es) |
AU (1) | AU2008315926A1 (es) |
CA (1) | CA2702962C (es) |
CL (1) | CL2008003122A1 (es) |
ES (1) | ES2527775T3 (es) |
IL (1) | IL205025A0 (es) |
MX (1) | MX2010004164A (es) |
PE (1) | PE20090975A1 (es) |
RU (1) | RU2520757C2 (es) |
TW (1) | TW200927762A (es) |
WO (1) | WO2009053038A2 (es) |
ZA (1) | ZA201002575B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS55723B1 (sr) * | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
CA2769595A1 (en) * | 2009-08-14 | 2011-02-17 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011060179A1 (en) * | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
EP2563391B1 (en) * | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
US8809282B2 (en) | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
TW201208703A (en) * | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
WO2012080389A1 (en) * | 2010-12-16 | 2012-06-21 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
US9272014B2 (en) | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
EP2704700B1 (en) * | 2011-04-29 | 2018-06-27 | Emory University | Selecting use of proteasome inhibitors based on nf-kb2 sequence |
US20140357596A1 (en) * | 2012-01-24 | 2014-12-04 | Millennium Pharmaceuticals, Inc. | Method of treatment of nasopharyngeal cancer |
EP2810066B1 (en) * | 2012-01-24 | 2019-07-31 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
BR112015022210A8 (pt) | 2013-03-13 | 2018-01-23 | Genentech Inc | formulações de anticorpo |
CN106794247B (zh) | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
PT1071700E (pt) * | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
MXPA02004599A (es) * | 1999-11-08 | 2002-10-23 | Idec Pharma Corp | Tratamiento de tumores malignos de celula b utilizando anticuerpos anti-cd40l en combinacion con anticuerpos anti-cd20 y/o agentes quimioterapeuticos y radioterapia. |
RU2306952C2 (ru) * | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
RS55723B1 (sr) * | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
EP1863513A2 (en) * | 2005-03-11 | 2007-12-12 | The University of North Carolina at Chapel Hill | Potent and specific immunoproteasome inhibitors |
EP1891113A2 (en) * | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
CN101291954B (zh) * | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
-
2008
- 2008-09-22 US US12/234,759 patent/US20090110688A1/en not_active Abandoned
- 2008-10-22 AU AU2008315926A patent/AU2008315926A1/en not_active Abandoned
- 2008-10-22 KR KR1020107009027A patent/KR101280733B1/ko not_active IP Right Cessation
- 2008-10-22 PE PE2008001813A patent/PE20090975A1/es not_active Application Discontinuation
- 2008-10-22 EP EP08841724.1A patent/EP2205318B1/en active Active
- 2008-10-22 JP JP2010530330A patent/JP5469073B2/ja active Active
- 2008-10-22 ES ES08841724.1T patent/ES2527775T3/es active Active
- 2008-10-22 WO PCT/EP2008/008919 patent/WO2009053038A2/en active Application Filing
- 2008-10-22 CA CA2702962A patent/CA2702962C/en not_active Expired - Fee Related
- 2008-10-22 RU RU2010120724/15A patent/RU2520757C2/ru not_active IP Right Cessation
- 2008-10-22 AR ARP080104606A patent/AR071733A1/es not_active Application Discontinuation
- 2008-10-22 CL CL2008003122A patent/CL2008003122A1/es unknown
- 2008-10-22 MX MX2010004164A patent/MX2010004164A/es active IP Right Grant
- 2008-10-23 TW TW097140695A patent/TW200927762A/zh unknown
-
2010
- 2010-04-12 IL IL205025A patent/IL205025A0/en unknown
- 2010-04-13 ZA ZA2010/02575A patent/ZA201002575B/en unknown
-
2011
- 2011-03-30 US US13/075,946 patent/US20110200598A1/en not_active Abandoned
-
2012
- 2012-05-04 US US13/464,664 patent/US20120219549A1/en not_active Abandoned
-
2014
- 2014-06-16 US US14/305,996 patent/US20160000912A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009053038A3 (en) | 2009-06-25 |
US20160000912A1 (en) | 2016-01-07 |
ZA201002575B (en) | 2011-04-28 |
TW200927762A (en) | 2009-07-01 |
JP2011500741A (ja) | 2011-01-06 |
CN102083499A (zh) | 2011-06-01 |
KR101280733B1 (ko) | 2013-07-02 |
AU2008315926A1 (en) | 2009-04-30 |
JP5469073B2 (ja) | 2014-04-09 |
CL2008003122A1 (es) | 2009-10-16 |
RU2520757C2 (ru) | 2014-06-27 |
RU2010120724A (ru) | 2012-05-20 |
KR20100068292A (ko) | 2010-06-22 |
ES2527775T3 (es) | 2015-01-29 |
MX2010004164A (es) | 2010-08-04 |
IL205025A0 (en) | 2010-11-30 |
PE20090975A1 (es) | 2009-07-13 |
US20090110688A1 (en) | 2009-04-30 |
WO2009053038A2 (en) | 2009-04-30 |
EP2205318B1 (en) | 2014-11-19 |
US20120219549A1 (en) | 2012-08-30 |
CA2702962A1 (en) | 2009-04-30 |
US20110200598A1 (en) | 2011-08-18 |
EP2205318A2 (en) | 2010-07-14 |
CA2702962C (en) | 2016-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071733A1 (es) | Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma | |
AR068818A1 (es) | Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit | |
AR072947A1 (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad, celular dependiente de anticuerpos (ccda) aumentada, composicion farmaceutica, anticuerpo anti-cd20 de tipo ii | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
PH12019501328A1 (en) | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors | |
CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
CL2011001256A1 (es) | Combinacion farmaceutica que comprende a un anticuerpo que reconoce especificamente a cd38, y ciclofosfamida, donde dicho anticuerpo es capaz de eliminar una celula cd38+ por apoptosis, citotoxicidad mediada por celulas dependiente de anticuerpo (adcc), y citotoxicidad dependiente de complemento (cdc). | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
AR074220A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
CL2008003788A1 (es) | Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20. | |
ES2571235T3 (es) | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
AR083293A1 (es) | Agentes de union a cd33 | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
CL2019000681A1 (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
CL2012002428A1 (es) | Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende. | |
CL2013003570A1 (es) | Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio. | |
AR075981A1 (es) | Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. uso | |
EA201301106A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНОВ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |